tiprankstipranks
Trending News
More News >

Alterity Therapeutics to Update on ATH434 Progress in Upcoming Fireside Chat

Story Highlights
  • Alterity Therapeutics focuses on neurodegenerative disease treatments, advancing ATH434 for Multiple System Atrophy.
  • CEO David Stamler will update on ATH434’s progress, following positive Phase 2 data, in a Fireside Chat.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Alterity Therapeutics to Update on ATH434 Progress in Upcoming Fireside Chat

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).

Alterity Therapeutics announced that its CEO, David Stamler, will provide a corporate update during a Fireside Chat hosted by MST Access, focusing on the progress of the ATH434 development program for Multiple System Atrophy. This announcement follows the positive Phase 2 data released in January, highlighting the company’s ongoing efforts to advance its clinical trials and strengthen its position in the biotechnology industry, potentially impacting stakeholders and the market for neurodegenerative disease treatments.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company is advancing its lead asset, ATH434, which has shown positive results in Phase 2 trials for Multiple System Atrophy (MSA), a rare Parkinsonian disorder. Alterity operates from Melbourne, Australia, and San Francisco, USA, and has a broad drug discovery platform aimed at addressing neurological disease pathology.

YTD Price Performance: 10.0%

Average Trading Volume: 14,450,003

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$100.4M

For an in-depth examination of ATH stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1